Practical implications for the administration of 13-cis retinoic acid in pediatric oncology
- 376 Downloads
Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.
Keywords13-cis retinoic acid Clinical pharmacy Pediatric oncology
Conflicts of interest
- 3.E-Compendium. Scientific Leaflet Roaccutane (in Flemish). Available from URL: http:/www.ecompendium.be/. Accessed 4 Oct 2010.
- 4.Matthay K, Reynolds C, Seeger R, Shimada H, Stanton Adkins E, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(7):1007–13.PubMedCrossRefGoogle Scholar
- 5.Veal GJ, Cole M, Errington J, Pearson A, Foot A, Whyman G, Boddy A. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma—a study of the United Kingdom Children’s Cancer Study Group. Br J Cancer. 2007;96(3):424–31.PubMedCrossRefGoogle Scholar
- 7.European Medicines Agency. List of paediatric needs oncology I. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004052.pdf. Accessed 18 Dec 2010.
- 8.Priority List of Needs in Pediatric Therapeutics for 2008–2009. National institutes of child health and human development. Available from URL: http://bpca.nichd.nih.gov/about/process/upload/2009-Summary-091509.pdf. Accessed 18 Dec 2010.